BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36272389)

  • 21. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mutational features of immunoglobulin heavy chain variable region gene in patients with chronic lymphocytic leukemia].
    Li YH; Huang XQ; Lin YN; Chen XJ; Chen L; Liu EB; Mi YC; Ru K
    Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1135-1140. PubMed ID: 36323543
    [No Abstract]   [Full Text] [Related]  

  • 23. Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia.
    Rout ED; Burnett RC; Labadie JD; Yoshimoto JA; Avery AC
    PLoS One; 2018; 13(1):e0191205. PubMed ID: 29385200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group.
    Kryachok I; Abramenko I; Bilous N; Chumak A; Martina Z; Filonenko I
    Med Oncol; 2012 Jun; 29(2):1093-101. PubMed ID: 21503826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia.
    Ghiotto F; Fais F; Albesiano E; Sison C; Valetto A; Gaidano G; Reinhardt J; Kolitz JE; Rai K; Allen SL; Ferrarini M; Chiorazzi N
    Mol Med; 2006; 12(11-12):300-8. PubMed ID: 17380195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia.
    Hadzidimitriou A; Darzentas N; Murray F; Smilevska T; Arvaniti E; Tresoldi C; Tsaftaris A; Laoutaris N; Anagnostopoulos A; Davi F; Ghia P; Rosenquist R; Stamatopoulos K; Belessi C
    Blood; 2009 Jan; 113(2):403-11. PubMed ID: 18948572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.
    Marasca R; Maffei R; Morselli M; Zucchini P; Castelli I; Martinelli S; Fontana M; Ravanetti S; Curotti M; Leonardi G; Cagossi K; Partesotti G; Torelli G
    J Mol Diagn; 2005 Nov; 7(5):566-74. PubMed ID: 16258154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
    Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
    Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
    Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
    Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
    Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.
    Widhopf GF; Goldberg CJ; Toy TL; Rassenti LZ; Wierda WG; Byrd JC; Keating MJ; Gribben JG; Rai KR; Kipps TJ
    Blood; 2008 Mar; 111(6):3137-44. PubMed ID: 17675554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.
    Ritgen M; Lange A; Stilgenbauer S; Dohner H; Bretscher C; Bosse H; Stuhr A; Kneba M; Dreger P
    Blood; 2003 Mar; 101(5):2049-53. PubMed ID: 12411304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia.
    Ghia EM; Widhopf GF; Rassenti LZ; Kipps TJ
    J Immunol; 2011 Jun; 186(11):6338-44. PubMed ID: 21525382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
    Ghia EM; Jain S; Widhopf GF; Rassenti LZ; Keating MJ; Wierda WG; Gribben JG; Brown JR; Rai KR; Byrd JC; Kay NE; Greaves AW; Kipps TJ
    Blood; 2008 May; 111(10):5101-8. PubMed ID: 18326815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
    Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
    Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course.
    Angotzi F; Cellini A; Ruocco V; Cavarretta CA; Zatta I; Serafin A; Pravato S; Pagnin E; Bonaldi L; Frezzato F; Facco M; Piazza F; Trentin L; Visentin A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis.
    Schettino EW; Cerutti A; Chiorazzi N; Casali P
    J Immunol; 1998 Jan; 160(2):820-30. PubMed ID: 9551917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution.
    Kostareli E; Sutton LA; Hadzidimitriou A; Darzentas N; Kouvatsi A; Tsaftaris A; Anagnostopoulos A; Rosenquist R; Stamatopoulos K
    Leukemia; 2010 Jul; 24(7):1317-24. PubMed ID: 20463750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.